Genetically determined telomere length and multiple myeloma risk and outcome
- Giaccherini M.
- Macauda A.
- Orciuolo E.
- Rymko M.
- Gruenpeter K.
- Dumontet C.
- Razny M.
- Moreno V.
- Buda G.
- Beider K.
- Varkonyi J.
- Avet-Loiseau H.
- Martinez-Lopez J.
- Marques H.
- Watek M.
- Sarasquete M. E.
- Andersen V.
- Karlin L.
- Suska A.
- Kruszewski M.
- Abildgaard N.
- Dudzinski M.
- Butrym A.
- Nagler A.
- Vangsted A. J.
- Kadar K.
- Waldemar T.
- Jamroziak K.
- Jacobsen S. E. H.
- Ebbesen L. H.
- Taszner M.
- Mazur G.
- Lesueur F.
- Pelosini M.
- Garcia-Sanz R.
- Jurczyszyn A.
- Demangel D.
- Reis R. M.
- Iskierka-Jazdzewska E.
- Markiewicz M.
- Gemignani F.
- Subocz E.
- Zawirska D.
- Druzd-Sitek A.
- Stepien A.
- Alonso M. H.
- Sainz J.
- Canzian F.
- Campa D.
DOIAbstract
Telomeres are involved in processes like cellular growth, chromosomal stability, and proper segregation to daughter cells. Telomere length measured in leukocytes (LTL) has been investigated in different cancer types, including multiple myeloma (MM). However, LTL measurement is prone to heterogeneity due to sample handling and study design (retrospective vs. prospective). LTL is genetically determined; genome-wide association studies identified 11 SNPs that, combined in a score, can be used as a genetic instrument to measure LTL and evaluate its association with MM risk. This approach has been already successfully attempted in various cancer types but never in MM. We tested the “teloscore” in 2407 MM patients and 1741 controls from the Inter...
Add to ORKG